RenovoRx (RNXT)
Market Price (5/26/2026): $0.8852 | Market Cap: $33.7 MilSector: Health Care | Industry: Biotechnology
RenovoRx (RNXT)
Market Price (5/26/2026): $0.8852Market Cap: $33.7 MilSector: Health CareIndustry: Biotechnology
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -36% Strong revenue growthRev Chg LTMRevenue Change % Last Twelve Months (LTM) is 520% Megatrend and thematic driversMegatrends include Precision Medicine, and Aging Population & Chronic Disease. Themes include Targeted Therapies, Biopharmaceutical R&D, Show more. | Weak multi-year price returns2Y Excs Rtn is -77%, 3Y Excs Rtn is -138% | Penny stockMkt Price is 0.9 Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -13 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -864% Significant share based compensationSBC/Rev LTMShare Based Compensation / Revenue (Sales), Last Twelve Months (LTM) is 87% Not cash flow generativeCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -759%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -759% Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -41% Key risksRNXT key risks include [1] an overwhelming dependence on the success of its single pivotal Phase III TIGeR-PaC clinical trial, Show more. |
| Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -36% |
| Strong revenue growthRev Chg LTMRevenue Change % Last Twelve Months (LTM) is 520% |
| Megatrend and thematic driversMegatrends include Precision Medicine, and Aging Population & Chronic Disease. Themes include Targeted Therapies, Biopharmaceutical R&D, Show more. |
| Weak multi-year price returns2Y Excs Rtn is -77%, 3Y Excs Rtn is -138% |
| Penny stockMkt Price is 0.9 |
| Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -13 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -864% |
| Significant share based compensationSBC/Rev LTMShare Based Compensation / Revenue (Sales), Last Twelve Months (LTM) is 87% |
| Not cash flow generativeCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -759%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -759% |
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -41% |
| Key risksRNXT key risks include [1] an overwhelming dependence on the success of its single pivotal Phase III TIGeR-PaC clinical trial, Show more. |
Qualitative Assessment
AI Analysis | Feedback
1. Persistent Net Losses and Cash Burn Continue to Weigh on Investor Sentiment.
RenovoRx reported a net loss of $3.5 million and negative operating cash flow of $3.7 million for the first quarter of 2026, despite a 136% quarter-over-quarter increase in revenue to $563,000. Although a $10.0 million private placement in March 2026 enhanced the company's cash position and extended its operational runway, the ongoing unprofitability raises concerns about its fundamental financial health.
2. Prolonged Await for Pivotal Clinical Trial Results Introduces Uncertainty.
The long-term value creation for RenovoRx remains heavily dependent on the successful outcome of its Phase III TIGeR-PaC trial for locally advanced pancreatic cancer, with final data not anticipated until mid to late 2027. While the trial is nearing full enrollment, with 106 out of 114 required patients randomized as of May 2026, the extended timeline and inherent risks associated with clinical trials contribute to investor uncertainty.
Show more
Stock Movement Drivers
Fundamental Drivers
The -15.2% change in RNXT stock from 1/31/2026 to 5/25/2026 was primarily driven by a -45.2% change in the company's P/S Multiple.| (LTM values as of) | 1312026 | 5252026 | Change |
|---|---|---|---|
| Stock Price ($) | 1.04 | 0.88 | -15.2% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 1 | 1 | 60.5% |
| P/S Multiple | 41.1 | 22.5 | -45.2% |
| Shares Outstanding (Mil) | 37 | 38 | -3.6% |
| Cumulative Contribution | -15.2% |
Market Drivers
1/31/2026 to 5/25/2026| Return | Correlation | |
|---|---|---|
| RNXT | -15.2% | |
| Market (SPY) | 8.1% | 20.2% |
| Sector (XLV) | -2.7% | 19.9% |
Fundamental Drivers
The -20.6% change in RNXT stock from 10/31/2025 to 5/25/2026 was primarily driven by a -63.3% change in the company's P/S Multiple.| (LTM values as of) | 10312025 | 5252026 | Change |
|---|---|---|---|
| Stock Price ($) | 1.11 | 0.88 | -20.6% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 1 | 1 | 124.9% |
| P/S Multiple | 61.3 | 22.5 | -63.3% |
| Shares Outstanding (Mil) | 37 | 38 | -3.8% |
| Cumulative Contribution | -20.6% |
Market Drivers
10/31/2025 to 5/25/2026| Return | Correlation | |
|---|---|---|
| RNXT | -20.6% | |
| Market (SPY) | 9.9% | 15.8% |
| Sector (XLV) | 4.8% | 20.6% |
Fundamental Drivers
The -8.2% change in RNXT stock from 4/30/2025 to 5/25/2026 was primarily driven by a -96.0% change in the company's P/S Multiple.| (LTM values as of) | 4302025 | 5252026 | Change |
|---|---|---|---|
| Stock Price ($) | 0.96 | 0.88 | -8.2% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 0 | 1 | 3362.8% |
| P/S Multiple | 560.5 | 22.5 | -96.0% |
| Shares Outstanding (Mil) | 25 | 38 | -34.0% |
| Cumulative Contribution | -8.2% |
Market Drivers
4/30/2025 to 5/25/2026| Return | Correlation | |
|---|---|---|
| RNXT | -8.2% | |
| Market (SPY) | 36.0% | 16.7% |
| Sector (XLV) | 8.6% | 14.8% |
Fundamental Drivers
The -71.8% change in RNXT stock from 4/30/2023 to 5/25/2026 was primarily driven by a null change in the company's P/S Multiple.| (LTM values as of) | 4302023 | 5252026 | Change |
|---|---|---|---|
| Stock Price ($) | 3.13 | 0.88 | -71.8% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 0 | 1 | 9.2233720368547763E17% |
| P/S Multiple | ∞ | 22.5 | |
| Shares Outstanding (Mil) | 9 | 38 | -76.1% |
| Cumulative Contribution | 0.0% |
Market Drivers
4/30/2023 to 5/25/2026| Return | Correlation | |
|---|---|---|
| RNXT | -71.8% | |
| Market (SPY) | 86.3% | 12.9% |
| Sector (XLV) | 18.0% | 10.1% |
Price Returns Compared
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| RNXT Return | -33% | -51% | -3% | -44% | -35% | 5% | -88% |
| Peers Return | -7% | 32% | 41% | -1% | 2% | 3% | 79% |
| S&P 500 Return | 27% | -19% | 24% | 23% | 16% | 9% | 98% |
Monthly Win Rates [3] | |||||||
| RNXT Win Rate | 40% | 50% | 33% | 42% | 25% | 60% | |
| Peers Win Rate | 42% | 67% | 58% | 50% | 67% | 45% | |
| S&P 500 Win Rate | 75% | 42% | 67% | 75% | 67% | 60% | |
Max Drawdowns [4] | |||||||
| RNXT Max Drawdown | - | -69% | -89% | -61% | -52% | -32% | |
| Peers Max Drawdown | -27% | -19% | -12% | -23% | -29% | -28% | |
| S&P 500 Max Drawdown | -5% | -25% | -10% | -8% | -19% | -9% | |
[1] Cumulative total returns since the beginning of 2021
[2] Peers: VRTX, ALPS, AVLN, DFTX, EIKN.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 5/22/2026 (YTD)
How Low Can It Go
| Event | RNXT | S&P 500 |
|---|---|---|
| 2025 US Tariff Shock | ||
| % Loss | -31.1% | -18.8% |
| % Gain to Breakeven | 45.1% | 23.1% |
| Time to Breakeven | 35 days | 79 days |
| Summer-Fall 2023 Five Percent Yield Shock | ||
| % Loss | -69.2% | -9.5% |
| % Gain to Breakeven | 225.0% | 10.5% |
| Time to Breakeven | 42 days | 24 days |
| 2022 Inflation Shock & Fed Tightening | ||
| % Loss | -69.0% | -24.5% |
| % Gain to Breakeven | 222.4% | 32.4% |
| Time to Breakeven | 294 days | 427 days |
In The Past
RenovoRx's stock fell -31.1% during the 2025 US Tariff Shock. Such a loss loss requires a 45.1% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
| Event | RNXT | S&P 500 |
|---|---|---|
| 2025 US Tariff Shock | ||
| % Loss | -31.1% | -18.8% |
| % Gain to Breakeven | 45.1% | 23.1% |
| Time to Breakeven | 35 days | 79 days |
| Summer-Fall 2023 Five Percent Yield Shock | ||
| % Loss | -69.2% | -9.5% |
| % Gain to Breakeven | 225.0% | 10.5% |
| Time to Breakeven | 42 days | 24 days |
| 2022 Inflation Shock & Fed Tightening | ||
| % Loss | -69.0% | -24.5% |
| % Gain to Breakeven | 222.4% | 32.4% |
| Time to Breakeven | 294 days | 427 days |
In The Past
RenovoRx's stock fell -31.1% during the 2025 US Tariff Shock. Such a loss loss requires a 45.1% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
About RenovoRx (RNXT)
AI Analysis | Feedback
1. Think of it like **Intuitive Surgical** (known for Da Vinci surgical robots), but instead of robots for surgery, RenovoRx uses a specialized catheter and delivery system to precisely target and treat solid tumors with chemotherapy.
2. It's like an early-stage **Moderna** or **BioNTech**, but instead of developing new mRNA vaccines, RenovoRx is creating a novel drug and device platform to improve how existing cancer drugs are delivered directly to tumors.
AI Analysis | Feedback
- RenovoGem: A drug and device combination therapy consisting of intra-arterial gemcitabine and RenovoCath, currently in Phase III clinical trials for locally advanced pancreatic cancer.
AI Analysis | Feedback
RenovoRx, Inc. (RNXT) is a clinical-stage biopharmaceutical company focused on developing therapies. Its lead product candidate, RenovoGem, is currently in Phase III clinical trials.
As a company primarily engaged in research, development, and clinical trials, RenovoRx does not currently have major commercial customers that purchase its products or services. Clinical-stage biopharmaceutical companies typically do not generate revenue from product sales until their therapies receive regulatory approval and are commercialized. Therefore, RenovoRx does not sell primarily to other companies or individuals at this stage.
AI Analysis | Feedback
nullAI Analysis | Feedback
Shaun R. Bagai Chief Executive Officer
Mr. Bagai has served as RenovoRx's Chief Executive Officer and a director since June 2014. Prior to joining RenovoRx, he led Global Market Development for HeartFlow, Inc. from 2011 to 2014, where he directed Japanese market research, regulatory/payer collaboration, and Key Opinion Leader development, and orchestrated their largest clinical trial. HeartFlow, Inc. later had an IPO in 2025. Mr. Bagai was also instrumental in developing the European market for renal denervation for Ardian, Inc., which led to its acquisition by Medtronic in 2011 for approximately $1 billion. He began his career in clinical research and medical device sales.
Mark Voll Chief Financial Officer
Mr. Voll was appointed Chief Financial Officer, effective February 1, 2026. He brings over three decades of financial leadership experience in the semiconductor and high-technology sectors. Mr. Voll has a track record of guiding high-growth companies through pivotal transitions, including IPOs, mergers, acquisitions, and large-scale operational expansion. He successfully guided companies through initial public offerings and subsequent exits, including Techwell, Inc. (IPO in 2006, acquired by Intersil in 2010), Montage Technology (IPO in 2013, acquired by PDSTI in 2014), and Aquantia Corporation (IPO in 2017, acquired by Marvell Technology in 2019).
Ramtin Agah, MD Executive Chairman, Chief Medical Officer, and Co-Founder
Dr. Agah has served as RenovoRx's Chief Medical Officer and Co-Founder since December 2009, and as Chairman of the Board since May 2018. He is an Interventional Cardiologist at El Camino Hospital, Mountain View, a role he began in September 2005, and has acted as a physician consultant for Abbott Vascular. Dr. Agah invented the double-balloon catheter (RenovoCath) that forms the foundation for RenovoRx's TAMP therapy platform, after observing challenges in isolating blood flow during a pancreatic cancer case.
Leesa Gentry Chief Clinical Officer
Ms. Gentry brings 29 years of experience focused on improving clinical research programs in the Contract Research Organization (CRO), pharmaceutical, and biotech industries. Her past employers include IQVIA (Quintiles), PPD, OmnicareCR, and Otsuka. At PPD, she was a Global Project Manager and Senior Research Specialist for Clinical Systems, where her team developed one of the pharmaceutical industry's first clinical trial management systems. Prior to RenovoRx, she was Senior Vice President of Clinical Operations at Evotec.
Ronald B. Kocak Vice President, Controller
Mr. Kocak serves as RenovoRx's Vice President and Controller. He was RenovoRx's interim controller in a consulting capacity since October 2021. Mr. Kocak is a seasoned financial reporting and accounting professional with extensive public company experience in the life sciences industry. Prior to joining RenovoRx, he was Controller and Senior Director of Finance at Sensei Biotherapeutics, Inc., where he led finance and accounting activities.
AI Analysis | Feedback
The key risks to RenovoRx's business, based on its status as a clinical-stage biopharmaceutical company with its lead product in Phase III trials, are as follows:- Clinical Development and Regulatory Approval Risk: RenovoRx's primary asset, RenovoGem, a drug and device combination, is currently undergoing Phase III clinical trials for locally advanced pancreatic cancer. Despite positive interim data suggesting a survival benefit and reduced adverse events, there is no guarantee that the ongoing clinical trials will achieve their primary endpoints, demonstrate sufficient efficacy or safety, or be completed on anticipated timelines. Failure or delays in these trials could severely impact the company's future. Furthermore, even with successful clinical trial outcomes, obtaining the necessary regulatory approvals (e.g., from the FDA) for commercialization is a complex, lengthy, and uncertain process that can involve additional requirements or delays.
- Financial Viability and Funding Risk: As a clinical-stage biopharmaceutical company, RenovoRx has consistently reported operating losses and negative cash flow, indicating a significant "cash burn." As of June 2025, the company had an estimated cash runway of approximately 14 months. The company explicitly states the need for additional financing to fund future operating expenses and capital requirements, with the potential for diluting current shareholder value through new equity issuances. The ability to secure sufficient capital to complete clinical trials and pursue commercialization remains a significant challenge.
- Competition and Market Access Risk: RenovoRx operates in a highly competitive and rapidly evolving environment for cancer therapies, particularly in treating pancreatic cancer, which has a notably poor 5-year survival rate. While RenovoGem has shown promising results, there is fierce competition from existing treatments and other companies developing novel therapies. Even if RenovoGem receives regulatory approval, the company faces substantial hurdles in achieving market acceptance, securing favorable pricing and reimbursement from payers, and establishing a robust commercial presence. Misalignment between trial endpoints and payer expectations can hinder market access, even for effective products.
AI Analysis | Feedback
nullAI Analysis | Feedback
RenovoRx, Inc. (RNXT) focuses on developing therapies for locally advanced pancreatic cancer (LAPC) with its lead product candidate, RenovoGem, a drug and device combination consisting of intra-arterial gemcitabine and RenovoCath. The addressable markets for RenovoRx's main products and services are as follows: * **Global Locally Advanced Pancreatic Cancer Market:** The global market for locally advanced pancreatic cancer was valued at US$ 1.31 billion in 2024 and is projected to reach US$ 2.38 billion by 2033, growing at a Compound Annual Growth Rate (CAGR) of 7.0% during the forecast period from 2025 to 2033. Another estimate indicates the global market will grow from USD 938.73 million in 2025 to USD 1680.33 million by 2031 at a 10.19% CAGR. * **North America Locally Advanced Pancreatic Cancer Market:** The North American market for locally advanced pancreatic cancer reached US$ 607.89 million in 2024 and is expected to reach US$ 1,086.35 million by 2033, demonstrating a CAGR of 6.7% during the forecast period from 2025 to 2033. The United States accounted for the highest pancreatic cancer treatment market size in the 7MM (United States, EU4 countries, the United Kingdom, and Japan) in 2024. * **RenovoCath (standalone device) U.S. Addressable Market:** RenovoRx believes the initial total addressable market for RenovoCath as a standalone device represents an estimated initial $400 million peak annual U.S. sales opportunity. The company anticipates this potential to expand into a several-billion-dollar total addressable market as it explores additional applications for its Trans-Arterial Micro-Perfusion (TAMP) technology. RenovoRx's TIGeR-PaC clinical trial for RenovoGem compares its RenovoTAMP therapy platform to standard-of-care systemic intravenous administration of gemcitabine and nab-paclitaxel, which has been associated with a $1 billion addressable market.AI Analysis | Feedback
Here are 3-5 expected drivers of future revenue growth for RenovoRx (RNXT) over the next 2-3 years:
- Expanding Commercial Adoption and Utilization of RenovoCath as a Standalone Device: RenovoRx has demonstrated significant commercial momentum for its FDA-cleared RenovoCath device, which is used for targeted drug delivery. The company has seen a substantial increase in its customer base, with 14 cancer centers approved to purchase RenovoCath by Q3 2025, up from five at the start of 2025. By February 2026, a total of 33 centers had requested access to RenovoCath, tripling the potential number of near-term commercial centers in RenovoRx's sales pipeline since Q1 2025. This expanding market presence, coupled with increasing repeat orders from existing customers, indicates a growing clinical demand for the device as it integrates into cancer treatment paradigms. Analysts project notable revenue growth for RenovoRx, reaching $1.3 million in 2025 and $4.5 million in 2026, primarily driven by RenovoCath sales and an expanding customer base. The availability of a new reimbursement code (C9797), offering $16,724 per Trans-Arterial Micro-Perfusion (TAMP) procedure, further supports commercial growth. RenovoRx also plans to add commercial personnel to meet expanding market demand.
- Potential FDA Approval and Commercialization of RenovoGem for Locally Advanced Pancreatic Cancer (LAPC): RenovoRx's lead product candidate, RenovoGem, a drug and device combination of intra-arterial gemcitabine and RenovoCath, is currently in a pivotal Phase III clinical trial (TIGeR-PaC) for locally advanced pancreatic cancer. The independent Data Monitoring Committee has provided positive recommendations to continue the trial, suggesting promising interim data. While final data from the trial is anticipated in 2027, the company expects to complete final enrollment by early 2026. A successful Phase III readout and subsequent FDA approval of RenovoGem for LAPC could be a significant catalyst for revenue growth, as it aims to establish a new standard of care for a cancer with a particularly poor prognosis.
- Expansion of the Trans-Arterial Micro-Perfusion (TAMP) Therapy Platform to Additional Solid Tumor Indications: Beyond its current focus on locally advanced pancreatic cancer, RenovoRx is actively pursuing the expansion of its proprietary TAMP therapy platform into other high unmet need oncology indications. The company's registry study is designed to generate data that could open doors for RenovoCath's use in other solid tumor types. RenovoRx aims for its platform to eventually address a "several billion dollar opportunity" as it expands into various tumor types. The company has also identified other potential pipeline opportunities in cancers such as extrahepatic Cholangiocarcinoma (eCCA), non-small cell lung cancer, uterine tumors, glioblastoma, and sarcoma. This strategic pipeline expansion, leveraging the existing TAMP platform, represents a significant long-term revenue growth driver.
AI Analysis | Feedback
Share Issuance
- In February 2025, RenovoRx closed a public offering of approximately 11.52 million shares of common stock at $1.05 per share, generating gross proceeds of about $12.1 million and net proceeds of approximately $10.9 million. These funds are intended for working capital, general corporate purposes, and advancing the Phase III TIGeR-PaC study and commercial sales of RenovoCath.
- The company completed two private placements in 2024, raising approximately $6.1 million in January and an additional $11.1 million in April, totaling $17.2 million in gross proceeds.
- In November 2025, RenovoRx filed a Form S-3 shelf registration, enabling them to offer up to $50 million of mixed securities to support working capital, the Phase III TIGeR-PaC study, and RenovoCath commercialization.
Inbound Investments
- The February 2025 public offering was supported by "multiple fundamental healthcare institutional investors."
- RenovoRx insiders, including management and the Board of Directors, participated in the January 2024 private placement, purchasing shares at $1.22 per share, demonstrating confidence in the company.
Capital Expenditures
- While specific capital expenditure figures are not consistently disclosed as distinct line items, the company's research and development expenses are significant. These expenses increased from $3.0 million in 2021 to $4.3 million in 2022, primarily driven by costs for contracted research, development, consulting, and a secondary manufacturer for the RenovoCath delivery system.
- As of September 30, 2025, RenovoRx reported approximately $1.0 million in accumulated depreciation and amortization.
Latest Trefis Analyses
| Title | Date | |
|---|---|---|
| DASHBOARDS | ||
| RenovoRx Earnings Notes | 12/16/2025 | |
| Is RenovoRx Stock Built to Withstand More Downside? | 10/17/2025 |
| Title | |
|---|---|
| ARTICLES |
Trade Ideas
Select ideas related to RNXT.
| Date | Ticker | Company | Category | Trade Strategy | 6M Fwd Rtn | 12M Fwd Rtn | 12M Max DD |
|---|---|---|---|---|---|---|---|
| 04302026 | GEHC | GE HealthCare Technologies | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 0.0% | 0.0% | 0.0% |
| 04302026 | IQV | IQVIA | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 0.0% | 0.0% | 0.0% |
| 04302026 | UHS | Universal Health Services | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 0.0% | 0.0% | 0.0% |
| 04302026 | ABT | Abbott Laboratories | Dip Buy | DB | P/E OPMDip Buy with Low PE and High MarginBuying dips for companies with tame PE and meaningfully high operating margin | 0.0% | 0.0% | 0.0% |
| 04302026 | ZBIO | Zenas BioPharma | Insider | Insider Buys 45DStrong Insider BuyingCompanies with multiple insider buys in the last 45 days | 0.0% | 0.0% | 0.0% |
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 16.70 |
| Mkt Cap | 1.4 |
| Rev LTM | 1 |
| Op Inc LTM | -103 |
| FCF LTM | -78 |
| FCF 3Y Avg | -10 |
| CFO LTM | -78 |
| CFO 3Y Avg | -10 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 265.2% |
| Rev Chg 3Y Avg | 9.9% |
| Rev Chg Q | 96.8% |
| QoQ Delta Rev Chg LTM | 17.2% |
| Op Inc Chg LTM | -10.9% |
| Op Inc Chg 3Y Avg | -8.1% |
| Op Mgn LTM | -413.1% |
| Op Mgn 3Y Avg | 24.1% |
| QoQ Delta Op Mgn LTM | 125.0% |
| CFO/Rev LTM | -362.1% |
| CFO/Rev 3Y Avg | 21.5% |
| FCF/Rev LTM | -364.3% |
| FCF/Rev 3Y Avg | 17.7% |
Valuation
| Median | |
|---|---|
| Name | |
| Mkt Cap | 1.4 |
| P/S | 15.8 |
| P/Op Inc | -1.9 |
| P/EBIT | -1.9 |
| P/E | -2.0 |
| P/CFO | -2.4 |
| Total Yield | -23.2% |
| Dividend Yield | 0.0% |
| FCF Yield 3Y Avg | -17.6% |
| D/E | 0.0 |
| Net D/E | -0.2 |
Returns
| Median | |
|---|---|
| Name | |
| 1M Rtn | 0.5% |
| 3M Rtn | -5.9% |
| 6M Rtn | 0.1% |
| 12M Rtn | -14.1% |
| 3Y Rtn | -14.7% |
| 1M Excs Rtn | -7.3% |
| 3M Excs Rtn | -15.2% |
| 6M Excs Rtn | -12.0% |
| 12M Excs Rtn | -42.6% |
| 3Y Excs Rtn | -94.4% |
Segment Financials
Revenue by Segment| $ Mil | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Developing novel targeted oncology therapies and offering RenovoCath delivery system as stand-alone | 0 | ||||
| Total | 0 |
| $ Mil | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Developing novel targeted oncology therapies and offering RenovoCath delivery system as stand-alone | -9 | ||||
| Total | -9 |
| $ Mil | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Developing novel targeted oncology therapies and offering RenovoCath delivery system as stand-alone | 1 | 7 | 16 | 2 | |
| Total | 1 | 7 | 16 | 2 |
Price Behavior
| Market Price | $0.88 | |
| Market Cap ($ Bil) | 0.0 | |
| First Trading Date | 08/26/2021 | |
| Distance from 52W High | -37.9% | |
| 50 Days | 200 Days | |
| DMA Price | $0.94 | $1.00 |
| DMA Trend | down | down |
| Distance from DMA | -6.3% | -11.6% |
| 3M | 1YR | |
| Volatility | 66.7% | 79.2% |
| Downside Capture | 178.81 | 257.32 |
| Upside Capture | 110.85 | 142.63 |
| Correlation (SPY) | 15.5% | 17.3% |
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | 0.60 | 0.66 | 0.82 | 1.03 | 1.06 | 0.85 |
| Up Beta | 0.10 | 0.49 | 0.65 | 1.10 | 0.54 | 0.22 |
| Down Beta | 12.17 | -1.65 | -0.16 | -0.71 | -0.45 | 0.23 |
| Up Capture | -71% | 106% | 98% | 137% | 193% | 163% |
| Bmk +ve Days | 15 | 22 | 31 | 66 | 141 | 428 |
| Stock +ve Days | 9 | 19 | 29 | 57 | 116 | 329 |
| Down Capture | 712% | 145% | 126% | 166% | 167% | 112% |
| Bmk -ve Days | 4 | 18 | 30 | 56 | 108 | 321 |
| Stock -ve Days | 12 | 23 | 34 | 67 | 124 | 377 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with RNXT | |
|---|---|---|---|---|
| RNXT | -28.9% | 79.0% | -0.09 | - |
| Sector ETF (XLV) | 16.0% | 14.5% | 0.80 | 15.0% |
| Equity (SPY) | 29.5% | 12.0% | 1.86 | 17.6% |
| Gold (GLD) | 35.5% | 26.8% | 1.11 | 3.0% |
| Commodities (DBC) | 42.9% | 18.7% | 1.77 | -4.5% |
| Real Estate (VNQ) | 15.2% | 13.1% | 0.82 | 20.0% |
| Bitcoin (BTCUSD) | -31.3% | 41.8% | -0.78 | 20.5% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with RNXT | |
|---|---|---|---|---|
| RNXT | -34.6% | 114.6% | 0.09 | - |
| Sector ETF (XLV) | 5.7% | 14.7% | 0.21 | 8.9% |
| Equity (SPY) | 14.0% | 17.0% | 0.64 | 13.3% |
| Gold (GLD) | 18.8% | 18.0% | 0.85 | 3.5% |
| Commodities (DBC) | 10.4% | 19.4% | 0.42 | 4.0% |
| Real Estate (VNQ) | 3.8% | 18.8% | 0.10 | 13.0% |
| Bitcoin (BTCUSD) | 11.6% | 55.3% | 0.41 | 6.1% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with RNXT | |
|---|---|---|---|---|
| RNXT | -19.1% | 114.6% | 0.09 | - |
| Sector ETF (XLV) | 9.9% | 16.5% | 0.49 | 8.9% |
| Equity (SPY) | 15.7% | 17.9% | 0.75 | 13.3% |
| Gold (GLD) | 13.0% | 16.0% | 0.67 | 3.5% |
| Commodities (DBC) | 7.8% | 17.9% | 0.35 | 4.0% |
| Real Estate (VNQ) | 5.5% | 20.7% | 0.23 | 13.0% |
| Bitcoin (BTCUSD) | 66.7% | 66.9% | 1.06 | 6.1% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Returns Analyses
Earnings Returns History
Expand for More| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 3/30/2026 | -5.6% | -15.9% | -22.3% |
| 11/13/2025 | -23.0% | -20.1% | -13.5% |
| 8/14/2025 | -22.9% | -28.0% | 2.4% |
| 4/1/2025 | -3.0% | -20.2% | -3.0% |
| 11/14/2024 | 0.0% | 9.2% | 17.4% |
| 11/14/2023 | -28.3% | -42.0% | -24.2% |
| 8/17/2023 | 7.6% | 2.3% | -2.9% |
| 5/15/2023 | 10.9% | 7.0% | -7.5% |
| ... | |||
| SUMMARY STATS | |||
| # Positive | 5 | 5 | 4 |
| # Negative | 8 | 8 | 9 |
| Median Positive | 2.7% | 2.3% | 5.8% |
| Median Negative | -9.3% | -20.2% | -22.3% |
| Max Positive | 10.9% | 9.2% | 17.4% |
| Max Negative | -28.3% | -42.0% | -43.0% |
SEC Filings
Expand for More| Report Date | Filing Date | Filing |
|---|---|---|
| 03/31/2026 | 05/14/2026 | 10-Q |
| 12/31/2025 | 03/30/2026 | 10-K |
| 09/30/2025 | 11/13/2025 | 10-Q |
| 06/30/2025 | 08/14/2025 | 10-Q |
| 03/31/2025 | 05/15/2025 | 10-Q |
| 12/31/2024 | 04/01/2025 | 10-K |
| 09/30/2024 | 11/13/2024 | 10-Q |
| 06/30/2024 | 08/13/2024 | 10-Q |
| 03/31/2024 | 05/10/2024 | 10-Q |
| 12/31/2023 | 04/01/2024 | 10-K |
| 09/30/2023 | 11/13/2023 | 10-Q |
| 06/30/2023 | 08/16/2023 | 10-Q |
| 03/31/2023 | 05/12/2023 | 10-Q |
| 12/31/2022 | 03/31/2023 | 10-K |
| 09/30/2022 | 11/14/2022 | 10-Q |
| 06/30/2022 | 08/12/2022 | 10-Q |
Recent Forward Guidance [BETA]
Latest: Q1 2026 Earnings Reported 5/14/2026
| Forward Guidance | Guidance Change | ||||||
|---|---|---|---|---|---|---|---|
| Metric | Low | Mid | High | % Chg | % Delta | Change | Prior |
| 2026 Revenue | 3.00 Mil | 3.50 Mil | 4.00 Mil | Affirmed | |||
| 2026 Active commercial cancer centers | 36 | ||||||
Insider Activity
Expand for More| # | Owner | Title | Holding | Action | Filing Date | Price | Shares | Transacted Value | Value of Held Shares | Form |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Voll, Mark | Chief Financial Officer | Direct | Buy | 5212026 | 0.79 | 25,000 | 19,690 | 112,138 | Form |
| 2 | Marton, Laurence | Laurence Marton Rollover IRA | Buy | 3242026 | 0.00 | 9,720 | Form | |||
| 3 | Bagai, Shaun | Chief Executive Officer | The Bagai Family Trust | Buy | 3242026 | 0.00 | 24,300 | Form | ||
| 4 | Voll, Mark | Chief Financial Officer | Voll Family Trust DTD 6/23/2010 Mark Voll TTEE | Buy | 3242026 | 0.00 | 97,200 | Form | ||
| 5 | Agah, Ramtin | Chief Medical Officer | Direct | Buy | 1222026 | 1.00 | 10,000 | 9,975 | 796,464 | Form |
Industry Resources
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.